

ASX Release



5 July 2006

PharmAust Wins International Supply Agreement for Low Cost Pain Killers

PharmAust Limited (ASX: PAA) has signed an international supply agreement that will see it offer low cost paracetamol and ibuprofen products to the \$200 million a year Australian and New Zealand analgesics markets.

The agreement – signed with Bristol Pharma Australia, a subsidiary of top 10 Indian pharmaceutical group IPCA - will see PharmAust obtain its own Therapeutic Goods Administration (TGA) registrations for paracetamol and ibuprofen in the fourth quarter of 2006, enabling it to supply retail grocery, community and hospital pharmacy markets.

Established in 1949, Bombay-based IPCA (formerly the Indian Pharmaceutical Combine Association) is a fully integrated pharmaceutical group with operations in over 100 countries. The company produces active pharmaceutical ingredients, generics and branded formulations.

IPCA currently employs 5000 staff worldwide and has subsidiaries in the USA, UK, South America, Nigeria and Brazil, with marketing offices in Russia, Kazakhstan, Ukraine, Vietnam, Philippines & Kenya.

In 2005, leading business magazine *Forbes Asia* selected IPCA as one of the first 200 'Best under a Billion Companies in Asia', for the third consecutive year. In 2004-05, IPCA launched 15 new pharmaceutical brands and five brand extensions. IPCA is a major player in Malaria Therapy with a 40% share of the anti-malarial market in India.

Bristol Pharma Australia Managing Director, Mr Alak Sundararaman, said: "Partnering with PharmAust creates synergies for both companies in supplying the Australian and New Zealand over the counter analgesics market, and will allow us to effectively offer more products through to this market via PharmAust's supply capabilities".

Further Comments:
Dr Paul D'Sylva
Managing Director PharmAust Limited
P: (08) 9284 8800 M: 0410 602 586

Media Enquiries:
Sarah Allchurch
Allchurch Communications
P: (08) 9381 6625 M: 0412 346 412

About PharmAust Limited – www.pharmaust.com

PharmAust Limited is a vertically integrated pharmaceutical group of companies involved in a range of activities from contract drug discovery and development to manufacturing, sales and marketing of healthcare & pharmaceutical products. PharmAust wholly owns three operating subsidiary companies:

PharmAust Manufacturing Pty Ltd manufactures and markets therapeutic and non-therapeutic pharmaceutical products for Australian and overseas markets.

Epichem Pty Ltd provides contract chemistry services alongside its own intellectual property generating research activities.

Mimotopes Pty Ltd provides products and services in discovery chemistry to the global pharmaceutical and biotechnology industries.

PharmAust Limited

Level 2, 45 Stirling Highway Nedlands Western Australia 6009 Australia

T: + 61 8 9284 8800

F: + 61 8 9284 8899

E: info@pharmaust.com

W: www.pharmaust.com